Clinical Trial Update: Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for enasidenib (AG-221) in adults with advanced solid tumors, glioma, or angioimmunoblastic T-cell lymphoma harboring IDH2 mutation; Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Glioma
• Solid Tumor

Drugs mentioned

• Enasidenib (enasidenib)

Snippet

Sponsor: Celgene | Conditions: Solid Tumor, Glioma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-23